Article metrics

Download PDFPDF
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)

 

Online download statistics by month:

Online download statistics by month: October 2021 to February 2023

AbstractFullPdf
Oct 202126323219
Nov 20215861718
Dec 202119477
Jan 202225767
Feb 2022414137
Mar 2022490911
Apr 202230723
May 202228646
Jun 20226423122
Jul 202236566
Aug 20224001514
Sep 202234290
Oct 2022333149
Nov 202229353
Dec 202238887
Jan 20231621310
Feb 2023400
Total8095191149